TKT and synovial sarcoma: Our study demonstrates that the novel TK inhibitor nilotinib exhibits higher antiproliferative activity than imatinib in two human STS cell lines, whereby synovial sarcoma SW982 cells appear significantly more sensitive than leiomyosarcoma SK-UT-1 cells.